Mark Tawfik , Angelica Rozenfeld , Chloé Lahoud , Sumeyye Ozer , Omer Alomari , Vincent DeChavez
{"title":"PD-1 inhibitor‐induced cytomegalovirus esophagitis in a patient with metastatic urothelial carcinoma: A case report","authors":"Mark Tawfik , Angelica Rozenfeld , Chloé Lahoud , Sumeyye Ozer , Omer Alomari , Vincent DeChavez","doi":"10.1016/j.hmedic.2025.100232","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Immune checkpoint inhibitors (ICIs), such as Pembrolizumab, have revolutionized cancer treatment. However, they pose challenges, specifically in the form of immune-related adverse events (irAEs). Although cases of gastrointestinal irAEs have been well-documented, the occurrence of cytomegalovirus (CMV) esophagitis months after immunotherapy discontinuation, has not been well reported.</div></div><div><h3>Case presentation</h3><div>We report a case of immune-related CMV esophagitis three months after discontinuing pembrolizumab therapy, which had been administered for metastatic urothelial cancer.</div></div><div><h3>Conclusion</h3><div>IrAE and their timing remain a challenge in patients receiving ICI therapy. CMV esophagitis is a rare irAE associated with ICIs and further investigation is needed to better develop effective treatment and prevention strategies.</div></div>","PeriodicalId":100908,"journal":{"name":"Medical Reports","volume":"12 ","pages":"Article 100232"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949918625000774","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Immune checkpoint inhibitors (ICIs), such as Pembrolizumab, have revolutionized cancer treatment. However, they pose challenges, specifically in the form of immune-related adverse events (irAEs). Although cases of gastrointestinal irAEs have been well-documented, the occurrence of cytomegalovirus (CMV) esophagitis months after immunotherapy discontinuation, has not been well reported.
Case presentation
We report a case of immune-related CMV esophagitis three months after discontinuing pembrolizumab therapy, which had been administered for metastatic urothelial cancer.
Conclusion
IrAE and their timing remain a challenge in patients receiving ICI therapy. CMV esophagitis is a rare irAE associated with ICIs and further investigation is needed to better develop effective treatment and prevention strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
